Jared Johnson breaks down why Jimmy Butler is one of the league's best players and why his managers have to be ecstatic with his play this season.
Attorney Jeremy Hogan retweeted defense lawyer James K. Filan on Monday evening. In the original tweet, Filan attached a copy of the Order and Final Judgment from the Delaware Chancery Court. The document revealed that the court had ruled in Ripple Labs’ favor, against the plaintiff, Tetragon Financial Group. Hogan, a partner at Hogan & … Continued
PC Charlie Harrison, 39, was sentenced to two years and three months in prison.
On April 8th, BYD ushered in a new milestone, as its Bahia SkyRail vehicle rolled off the production line in Shenzhen. The Bahia SkyRail, located in the city of Salvador, Bahia State, Brazil, is the world’s first SkyRail line to be partially built above the sea.
PALO ALTO, Calif. and BUFFALO, N.Y., April 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a collaboration with Roswell Park Comprehensive Cancer Center to advance the development of investigational therapeutics for patients with genetically driven cancers. “We are honored to begin collaborating with Roswell Park, which is renowned for its excellence in cancer research and its mission to set the gold standard for treating patients with genetically driven cancers,” said BridgeBio CEO and founder Neil Kumar, Ph.D. Under the partnership, BridgeBio will work with scientists at Roswell Park Comprehensive Cancer Center to evaluate new research and development opportunities in oncology that have promise to advance and potentially provide clinical benefit for patients. Select therapeutic programs may be pursued by BridgeBio, in close collaboration with Roswell Park Comprehensive Cancer Center scientists, who would remain deeply involved in the ongoing development of these investigational therapies. “Collaborating with BridgeBio opens up a platform of new resources to support the incredible Roswell Park innovators working on new ways to care for cancer patients with dire unmet need,” said Roswell Park Comprehensive Cancer Center President and CEO Candace S. Johnson, Ph.D. “The ability to tap into this network of expertise means greater visibility for our teams and enables a quicker path to the clinic for our most promising ideas and inventions in areas like genetics, bioinformatics and molecular biology.” BridgeBio partners with stand-out academic institutions, including Roswell Park Comprehensive Cancer Center, to support research around genetically driven conditions and is focused on rapidly translating findings into meaningful treatments for patients. Today BridgeBio also announced formal partnerships with Brown University, GlycoNet, The Lundquist Institute, Oregon Health & Science University, University of California, Davis and University of California, San Diego – for a total of 20 partnerships between BridgeBio and leading academic and research institutions to date. For a list of some of the institutions BridgeBio is partnered with, please visit Our Partners page. With a diverse pipeline encompassing investigational therapies for both rare diseases and genetically validated cancers, BridgeBio provides the insights and support needed to rapidly progress therapeutic research from labs to clinical development. BridgeBio intends to develop similar long-term partnerships based on trust, engagement, science and respect to support its mission of developing life-changing medicines for patients with genetically driven conditions as quickly and safely as possible. About Roswell Park Comprehensive Cancer CenterRoswell Park Comprehensive Cancer Center is a community united by the drive to eliminate cancer’s grip on humanity by unlocking its secrets through personalized approaches and unleashing the healing power of hope. Founded by Dr. Roswell Park in 1898, it is the only National Cancer Institute-designated comprehensive cancer center in Upstate New York. Learn more at www.roswellpark.org, or contact us at 1-800-ROSWELL (1-800-767-9355) or ASKRoswell@RoswellPark.org. About BridgeBio PharmaBridgeBio is a biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio’s pipeline of over 30 development programs ranges from early science to advanced clinical trials and its commercial organization is focused on delivering the company’s first approved therapy. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com. BridgeBio Pharma Forward-Looking StatementsThis press release contains forward-looking statements. Statements we make in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements, including statements relating to expectations, plans, and prospects regarding our ability to build on the significant advances being made in Roswell Park’s labs and translate them into meaningful medicines for patients in need, the success of current and future relationships with third-party collaborators and academic partners, and the potential ability of our product candidates to treat genetically driven cancers, reflect our current views about our plans, intentions, expectations, strategies and prospects, and are based on the information currently available to us and on assumptions we have made and are neither forecasts, promises nor guarantees. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by these forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, the success of our product candidates to treat genetically driven cancers, the success of our collaboration with Roswell Park, as well as those risks set forth in the Risk Factors section of BridgeBio Pharma’s most recent Annual Report on Form 10-K and BridgeBio Pharma’s other SEC filings. Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Roswell Park Contact:Annie Deck-MillerAnn.Deck-Miller@RoswellPark.org716-845-8593 BridgeBio Contact:Grace RauhBridgeBio Pharma, Inc.Grace.rauh@bridgebio.com(917) 232-5478
Britain began offering coronavirus vaccinations to anyone over 45 on Tuesday after hitting its target of giving at last one dose to everyone over 50 by the middle of April. Despite the good news, Prime Minister Boris Johnson warned that the U.K. would inevitably see “more hospitalization and deaths” as it emerges from lockdown. More than 32 million people, over 60% of the country's adults, have had a first shot and almost 15% of adults have gotten both doses.
The quest to secure Premier League survival has reached a critical stage.
Central Ohio Urology Group, a leading provider of urological services with network of 15 offices in the region, adds seasoned leader Jason Thomas.
Dublin, April 13, 2021 (GLOBE NEWSWIRE) -- The "Lubricating Oil Additives - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Amid the COVID-19 crisis, the global market for Lubricating Oil Additives estimated at US$15.7 Billion in the year 2020, is projected to reach a revised size of US$19 Billion by 2027, growing at a CAGR of 2.8% over the analysis period 2020-2027. Dispersants, one of the segments analyzed in the report, is projected to record a 2.4% CAGR and reach US$4.7 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Viscosity Index Improvers segment is readjusted to a revised 2.4% CAGR for the next 7-year period.The U.S. Market is Estimated at $4.2 Billion, While China is Forecast to Grow at 4.5% CAGRThe Lubricating Oil Additives market in the U.S. is estimated at US$4.2 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$3.6 Billion by the year 2027 trailing a CAGR of 4.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.8% and 2.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 2.2% CAGR.Detergents Segment to Record 2.6% CAGRIn the global Detergents segment, USA, Canada, Japan, China and Europe will drive the 2.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.6 Billion in the year 2020 will reach a projected size of US$2 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$2.4 Billion by the year 2027, while Latin America will expand at a 2.7% CAGR through the analysis period.Select Competitors (Total 45 Featured): Afton ChemicalBASF SEBRB InternationalChevron CorporationCroda International PLCDorfketal Chemicals (I) Pvt LtdDover Chemical CorporationEvonik Industries AGInfineum International LimitedKing Industries Inc.LanxessMultisolR.T. Vanderbilt Holding Company, Inc.Shepherd ChemicalThe Elco CorporationThe Lubrizol CorporationWuxi South Petroleum Additives Co., Ltd. Key Topics Covered: I. METHODOLOGYII. EXECUTIVE SUMMARY1. MARKET OVERVIEW Influencer Market InsightsWorld Market TrajectoriesImpact of Covid-19 and a Looming Global Recession 2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS4. GLOBAL MARKET PERSPECTIVEIII. MARKET ANALYSIS UNITED STATESCANADAJAPANCHINAEUROPEFRANCEGERMANYITALYUNITED KINGDOMSPAINRUSSIAREST OF EUROPEASIA-PACIFICAUSTRALIAINDIASOUTH KOREAREST OF ASIA-PACIFICLATIN AMERICAARGENTINABRAZILMEXICOREST OF LATIN AMERICAMIDDLE EASTIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTAFRICA IV. COMPETITION Total Companies Profiled: 45 For more information about this report visit https://www.researchandmarkets.com/r/hqcim1 CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Pre-specified interim analysis concluded with favorable recommendation to continue the LUNAR trial DMC stated accrual to 534 patients is likely unnecessary and possibly unethical for patients randomized to control arm and recommended a shortened trial SHANGHAI and SAN FRANCISCO and ST. HELIER, Jersey, April 13, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and Novocure (NASDAQ: NVCR) today announced an update regarding its phase 3 pivotal LUNAR trial of Tumor Treating Fields (TTFields) in stage 4 non-small cell lung cancer (NSCLC) following platinum failure. Following a routine review of the study by an independent data monitoring committee (DMC), Novocure was informed that the pre-specified interim analysis for the LUNAR trial would be accelerated given the length of accrual and the number of events observed, to date. The interim analysis included data from 210 patients accrued to the LUNAR trial through February 2021. After review of the interim analysis report, the DMC concluded that the LUNAR trial should continue with no evidence of increased systemic toxicity. The DMC also stated that it is likely unnecessary and possibly unethical for patients randomized to the control arm to continue accrual to 534 patients with 18 months follow-up. The DMC recommended a reduced sample size of approximately 276 patients with 12 months follow-up which it believes will provide sufficient overall power for both primary and secondary endpoints. The DMC recommended no other changes to the design of the trial. Novocure remains blinded to all data. The primary endpoint of the LUNAR trial is superior overall survival when patients are treated with TTFields plus immune checkpoint inhibitors or docetaxel versus immune checkpoint inhibitors or docetaxel alone. The final analysis will also include an analysis of overall survival in the immune checkpoint inhibitor and docetaxel treatment subgroups. Novocure has notified the U.S. Food and Drug Administration (FDA) of the DMC recommendations and of its intent to submit an Investigational Device Exemption (IDE) supplement incorporating the recommended protocol adjustments. “We are very pleased with the DMC recommendations, which we believe support the potential for TTFields to make a significant difference in treatment outcomes for patients with non-small cell lung cancer, whether used together with immune checkpoint inhibitors or docetaxel,” said William Doyle, Novocure’s Executive Chairman. “The accelerated interim analysis with an encouraging outcome adds to the accumulating evidence of Tumor Treating Fields’ broad potential across a range of hard-to-treat cancers.” “Combination therapy is a cornerstone of cancer care, and we believe using TTFields together with other cancer treatments, including immunotherapies, may lead to better outcomes for some patients,” continued Mr. Doyle. “We are very encouraged that, consistent with our expectations, the DMC concluded that TTFields exhibited no systemic toxicity. We will continue to develop TTFields as a limited toxicity backbone therapy upon which other standard-of-care and emerging cancer treatments can be added.” Lung cancer is the most common cause of cancer-related death worldwide, and NSCLC accounts for approximately 85% of all lung cancers. It is estimated that approximately 193,000 patients are diagnosed with NSCLC each year in the U.S. and approximately 46,000 patients receive second-line treatment for stage 4 NSCLC each year in the U.S. Physicians use different combinations of surgery, radiation and pharmacological therapies to treat NSCLC, depending on the stage of the disease. TTFields is intended principally for use together with other standard-of-care treatments, and LUNAR was designed to generate data that contemplates multiple outcomes, all of which Novocure believes will be clinically meaningful. “The completion of the LUNAR interim analysis is an important milestone for Novocure,” said Asaf Danziger, Novocure’s CEO. “We are grateful to the DMC members for their diligence, guidance and support, and are looking forward to working closely with the FDA on amendments to the protocol given the DMC’s recommendations. Pending regulatory approval, the recommended protocol adjustments could accelerate trial completion by more than a year. We look forward to sharing final data from the LUNAR trial as quickly as possible.” About NSCLC in ChinaLung cancer consists of NSCLC in approximately 85% of cases and small cell lung cancer (SCLC) in approximately 15% of cases. Lung cancer has the highest total incidence of any cancer in China. According to the World Health Organization, the incidence of lung cancer in China in 2020 was 815,563 cases, with 714,699 deaths. In China, the five-year survival rate of lung cancer is estimated to be about 20%. About LUNARLUNAR is a phase 3 pivotal trial testing the effectiveness of TTFields in combination with immune checkpoint inhibitors or docetaxel versus immune checkpoint inhibitors or docetaxel alone for patients with stage 4 NSCLC who progressed during or after platinum-based therapy. It is estimated that approximately 46,000 patients receive second-line treatment for stage 4 NSCLC each year in the U.S. The primary endpoint is superior overall survival of patients treated with TTFields plus immune checkpoint inhibitors or docetaxel versus immune checkpoint inhibitors or docetaxel alone. TTFields is intended principally for use in combination with other standard-of-care treatments, and LUNAR was designed to generate data that contemplates multiple outcomes, all of which Novocure believes will be clinically meaningful. About Tumor Treating FieldsTumor Treating Fields, or TTFields, are electric fields that disrupt cancer cell division. When cancer develops, rapid and uncontrolled division of unhealthy cells occurs. Electrically charged proteins within the cell are critical for cell division, making the rapidly dividing cancer cells vulnerable to electrical interference. All cells are surrounded by a bilipid membrane, which separates the interior of the cell, or cytoplasm, from the space around it. This membrane prevents low frequency electric fields from entering the cell. TTFields, however, have a unique frequency range, between 100 to 500 kHz, enabling the electric fields to penetrate the cancer cell membrane. As healthy cells differ from cancer cells in their division rate, geometry and electric properties, the frequency of TTFields can be tuned to specifically affect the cancer cells while leaving healthy cells mostly unaffected. Whether cells are healthy or cancerous, cell division, or mitosis, is the same. When mitosis starts, charged proteins within the cell, or microtubules, form the mitotic spindle. The spindle is built on electric interaction between its building blocks. During division, the mitotic spindle segregates the chromosomes, pulling them in opposite directions. As the daughter cells begin to form, electrically polarized molecules migrate towards the midline to make up the mitotic cleavage furrow. The furrow contracts and the two daughter cells separate. TTFields can interfere with these conditions. When TTFields are present in a dividing cancer cell, they cause the electrically charged proteins to align with the directional forces applied by the field, thus preventing the mitotic spindle from forming. Electrical forces also interrupt the migration of key proteins to the cell midline, disrupting the formation of the mitotic cleavage furrow. Interfering with these key processes disrupts mitosis and can lead to cell death. TTFields is intended principally for use together with other standard-of-care cancer treatments. There is a growing body of evidence that supports TTFields' broad applicability with certain other cancer therapies, including radiation therapy, certain chemotherapies and certain immunotherapies. In clinical research and commercial experience to date, TTFields has exhibited no systemic toxicity, with mild to moderate skin irritation being the most common side effect. Fundamental scientific research extends across two decades and, in all preclinical research to date, TTFields has demonstrated a consistent anti-mitotic effect. The TTFields global development program includes a broad range of clinical trials across all phases, included four phase 3 pivotal trials in a variety of tumor types. To date, more than 18,000 patients have been treated with TTFields. Use of Tumor Treating Fields for the treatment of NSCLC is investigational only. About Zai LabZai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative commercial-stage biopharmaceutical company focused on bringing transformative medicines for cancer and infectious and autoimmune diseases to patients in China and around the world. We aim to address significant unmet medical needs in large, fast-growing segments of the pharmaceutical market. Our experienced team has secured partnerships with leading global biopharmaceutical companies to generate a broad pipeline of potentially innovative, marketed products and product candidates. We have also built an in-house team with strong drug discovery and translational research capabilities and are establishing a pipeline of proprietary drug candidates with global rights. Our vision is to become a leading global biopharmaceutical company, discovering, developing, manufacturing and commercializing our portfolio in order to positively impact human health worldwide. For additional information about the company, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global. About NovocureNovocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, TTFields. TTFields are electric fields that disrupt cancer cell division. Novocure’s commercialized products are approved for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer. Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City. Additionally, the company has offices in Germany, Switzerland, Japan and Israel. For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure. Zai Lab Forward-Looking StatementsThis press release contains statements about future expectations, plans and prospects for Zai Lab, including, without limitation, statements regarding the prospects and plans for developing and commercializing Tumor Treating Fields in Greater China and other statements containing words such as “anticipates”, “believes”, “expects”, “plans”, “can be” and other similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact nor are they guarantees or assurances of future performance. Forward-looking statements are based on Zai Lab’s expectations and assumptions as of the date of this press release and are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including but not limited to (1) Zai Lab’s ability to successfully commercialize and generate revenue from its approved products; (2) Zai Lab’s ability to finance its operations and business initiatives and obtain funding for such activities, (3) Zai Lab’s results of clinical and pre-clinical development of its product candidates, (4) the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of Zai Lab’s product candidates, (5) the effects of the novel coronavirus (COVID-19) pandemic on general economic, regulatory and political conditions and (6) other factors discussed in Zai Lab’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed on March 1, 2021, and its other filings with the Securities and Exchange Commission. Zai Lab anticipates that subsequent events and developments will cause Zai Lab’s expectations and assumptions to change and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. These forward-looking statements should not be relied upon as representing Zai Lab’s views as of any date subsequent to the date of this press release. Novocure Forward-Looking StatementsIn addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding LUNAR progress and timelines, interpretation of the LUNAR interim analysis, anticipated scientific progress on its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions as well as issues arising from the COVID-19 pandemic and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 25, 2021, with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion. ZAI LAB CONTACTS:Zai LabBilly Cho, CFO+86 137 6151 2501 billy.cho@zailaboratory.com Media: Ryo Imai / Robert Flamm, Ph.D.Burns McClellan, on behalf of Zai Lab212-213-0006 ext. 315 / 364rimai@burnsmc.com / rflamm@burnsmc.com Investors: Mike ZanoniEndurance Advisors, on behalf of Zai Lab610-442-8570mzanoni@enduranceadvisors.com Media and Investor Contact:Ashley Cordova(212)767-7558media@novocure.cominvestorinfo@novocure.com Zai Lab Limited
PALO ALTO, Calif., April 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a collaboration with Oregon Health & Science University (OHSU) in Portland, Oregon, to advance research and the development of investigational medicines for patients with genetically driven conditions. “We feel privileged to have the opportunity to work with OHSU to focus on developing potential therapies for diseases with clear genetic drivers and severe unmet need,” said BridgeBio founder and CEO Neil Kumar, Ph.D. “OHSU was one of the first research institutions we connected with in the early days of BridgeBio, and we look forward to deepening our relationship through close collaboration with their scientists as we strive to help patients together.” This arrangement builds on five years of informal collaborations between the two organizations. Under the agreement, the BridgeBio team will work closely with OHSU scientists and investigators to advance potential medicines for patients with genetically driven conditions, including cancers. “BridgeBio’s approach to identifying and developing novel therapies allows them to interact with multiple investigators at OHSU who are studying a wide variety of diseases,” said OHSU Chief Research Officer and Executive Vice President Peter Barr-Gillespie, Ph.D. “We believe their expertise and infrastructure will help lead to the rapid development of new drugs. We see this collaboration as an important part of our efforts to bring OHSU innovations to clinical significance.” BridgeBio collaborates with stand-out academic institutions, including OHSU, to support research around genetically driven conditions and is focused on rapidly translating findings into meaningful treatments for patients. Today BridgeBio also announced formal partnerships with Brown University, GlycoNet, The Lundquist Institute, Roswell Park Comprehensive Cancer Center, University of California, Davis and University of California, San Diego – for a total of 20 partnerships between BridgeBio and leading academic and research institutions to date. For a list of some of the institutions BridgeBio partners with, please visit Our Partners page. With a diverse pipeline encompassing investigational therapies for rare diseases and genetically validated cancers, BridgeBio provides the insights and support needed to rapidly progress therapeutic research from labs to clinical development. BridgeBio intends to develop similar long-term partnerships based on trust, engagement, science and respect to support its mission of developing life-changing medicines for patients with genetically driven conditions as quickly and safely as possible. About BridgeBio PharmaBridgeBio is a biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio’s pipeline of over 30 development programs ranges from early science to advanced clinical trials and its commercial organization is focused on delivering the company’s first approved therapy. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com. BridgeBio Pharma Forward-Looking StatementsThis press release contains forward-looking statements. Statements we make in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements, including statements relating to expectations, plans, and prospects regarding our ability to build on the significant advances being made in OHSU’s labs and translate them into meaningful medicines for patients in need, the success of current and future relationships with third-party collaborators and academic partners, and the potential ability of our product candidates to treat genetically driven diseases and cancers with clear genetic drivers, reflect our current views about our plans, intentions, expectations, strategies and prospects, and are based on the information currently available to us and on assumptions we have made and are neither forecasts, promises nor guarantees. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by these forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, the success of our product candidates to treat genetically driven diseases and cancers with clear genetic drivers, the success of our collaboration with OHSU, as well as those risks set forth in the Risk Factors section of BridgeBio Pharma’s most recent Annual Report on Form 10-K and BridgeBio Pharma’s other SEC filings. Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. OHSU Contact:Erik Robinsonrobineri@ohsu.edu(503) 494-8231 BridgeBio Contact:Grace RauhBridgeBio Pharma, Inc.Grace.rauh@bridgebio.com(917) 232-5478
Every bottle of fine wine starts with a vineyard filled with extraordinary grapes. It communicates that special place and deserves to arrive at its destination in exceptional condition. 00 Wines and Liviri announce a partnership dedicated to achieving a more sustainable future. This partnership was forged to reduce environmental impact by replacing use of traditional insulated corrugated cardboard wine shipping boxes with the reusable Liviri Vino6.
Some of Britain's favourite words were projected onto buildings around London to mark the easing of lockdown restrictions and National Scrabble Day on Tuesday. Words like "freedom", "hope", "family" and "beer" to represent the mood of the nation were beamed in the style of the game's letter tiles onto a pub, shops and locations near landmarks such as the Harrods department store and the Shard skyscraper. "Scrabble is projecting the nation's favourite words to coincide with the lockdown lifting in the UK and National Scrabble Day," said company spokeswoman Amarilis Whitty.
Albion are eight points from safety with seven games left.
Forecasts by Source (Autologous, Allogenic, Other Sources), by Application (Orthopaedics, Dermatology, Dental, Cardiac Muscle Injury, Nerve Injury, Other Applications), by Type (Pure PRP, Leucocyte-rich PRP, Pure Platelet-rich Fibrin (PRF), Leukocyte-rich Fibrin (L-PRF)), by End-user (Hospitals, Clinics & Care Centres, Research Institutes, Other End-user) and Leading National Market Analysis PLUS Analysis of Leading Plasma Therapy Companies AND COVID-19 Recovery Scenarios.New York, April 13, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Plasma Therapy Market Report 2021-2031" - https://www.reportlinker.com/p06058552/?utm_source=GNW What is holding you back from greater success in the Plasma Therapy market? Though Plasma therapy is not new, the gap between plasma’s demand and supply continues to grow. Many plasma therapy companies are unable to make a move and grab this opportunity – why? In this report we have analysed the plasma therapy market to discover the key success areas to grow during this tough crisis. Buy this unique senior level report to find out how to succeed – TODAY. Our 360+ page report provides 277 tables, 275 charts, and graphs. Read on to discover the most lucrative areas in the global plasma therapy industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing plasma therapy market. Buy our report to see how to exploit these opportunities in the global market. Forecasts to 2031 and other analyses reveal the commercial prospects • In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares. • You find original analyses, with business outlooks and developments. • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), Porter’s Five Forces Analysis, product profiles and commercial developments. Discover sales predictions for the global plasma therapy market and submarkets Along with revenue prediction for the overall world market, there are 5 segmentations of the plasma therapy market, with forecasts for 4 product types, 6 applications, 3 sources, 4 end-users each forecasted at a global, regional, and country level, along with COVID-19 impact recovery pattern analysis for all segments. Leading companies and the potential for market growth As per the analysis, the overall world revenue for plasma therapy will surpass US$816.5 million by 2031. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead. What all Segments are Covered in the Report? Global Plasma Therapy Market by Source (COVID-19 Impact Recovery Analysis Covered) • Autologous • Allogenic • Other Sources Global Plasma Therapy Market by Application (COVID-19 Impact Recovery Analysis Covered) • Orthopaedics • Dermatology • Dental • Cardiac Muscle Injury • Nerve Injury • Other Applications Global Plasma Therapy Market by Type (COVID-19 Impact Recovery Analysis Covered) • Pure PRP • Leucocyte-rich PRP • Pure Platelet-rich Fibrin (PRF) • Leukocyte-rich Fibrin (L-PRF) Global Plasma Therapy Market by End-User (COVID-19 Impact Recovery Analysis Covered) • Hospitals • Clinics & Care Centres • Research Institutes • Other End-User Global Plasma Therapy Market by Region (COVID-19 Impact Recovery Analysis Covered) • North America • Europe • Asia-Pacific • Latin America • Middle East • Africa Which Key Players Are Leading the Global Market and how much share do they hold? The global market for blood plasma therapy is ascending and has made significant gains in therapeutic treatments. The players in the blood plasma market are striving to tap the opportunities that this market offers. Companies are trying to explore the available prospects by adopting various strategies such as: • Mergers and acquisitions. • Product launches. • Collaborations and partnerships. Product approval is a major milestone facing all key competitors in the blood plasma therapy market. Several strategies were implemented by key market players between 2015 and April 2019. The threat of transmission of blood-borne diseases can make regulation that ensures the safety and efficacy of blood plasma proteins and blood plasma therapies unavoidable. How the Plasma Therapy Market report helps you? Buy this report to find answers for below questions and how can help you to stay updated • What is the current size of the overall global human plasma therapy market? How much will this market be worth from 2021 to 2031? • How will market shares of the leading national markets change by 2031, and which geographical region will lead the market in 2031? • Who are the leading companies and what are their activities, results, developments and prospects? • What are some of the most prominent human plasma therapy currently in development? • What are the main trends that will affect the world plasma therapy market between 2021 and 2031? • What are the main strengths, weaknesses, opportunities and threats for the market? • What are the social, technological, economic and political influences that will shape that industry over the next ten years? • How will the global plasma therapy market evolve over the forecasted period, 2021 to 2031? • How will the market shares for each checkpoint inhibitor anti-cancer treatment submarket develop from 2021 to 2031? • Which therapies can succeed and what revenues could they generate to 2031? • What will be the main commercial drivers for the market from 2021 to 2031? • How will market shares of prominent national markets change from 2021, and which countries will lead the market in 2031, achieving highest revenues and fastest growth? • How will that industry evolve between 2021 and 2031, especially in R&D? Leading Players Profiled in the Report • Biotest AG • CSL Limited • Grifols International S.A • China Biologic Products Holdings, Inc. • Terumo Corporation • Johnson & Johnson • Zimmer Biomet Holdings, Inc. • Stryker Corporation • Thermogenesis Holdings, Inc., • Nuo Therapeutics, Inc., Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence. Information found nowhere else With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. This study is for everybody needing commercial analyses for the precision cancer diagnostic tests Market and leading companies. You will find data, trends and predictions.Read the full report: https://www.reportlinker.com/p06058552/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001
Prince Philip's love of sailing was also fostered during his time at Gordonstoun, in Scotland.
Lion Group Holding Ltd. ("Lion" or "the Company") (NASDAQ: LGHL), operator of an all-in-one trading platform that offers a wide spectrum of products and services with a focus on Chinese investors, entered into a share purchase agreement (the "Share Purchase Agreement") with Mr. Jian Wang (the "Seller"), a majority shareholder and director of the Company, in a single transaction, to acquire the whole of the issued share capital of Lion Fintech Group Limited. At closing, Lion Fintech Group Limited will become a wholly-owned subsidiary of the Company.
The "Building Information Modeling Market By Component Deployment Mode, Project Life Cycle, Building Type, Application, and End User: Global Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.
Partner Communications Company Ltd. ("Partner" or the "Company") (NASDAQ: PTNR) (TASE: PTNR), a leading Israeli communications operator, announces that, following the Company's report dated February 21, 2021, the Company decided to reject the bids received from various investors to acquire 20% of the rights to use the Company's existing and future fiber optic network for services to private households.
TORRANCE, Calif. and PALO ALTO, Calif., April 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO) and The Lundquist Institute for Biomedical Innovation at the Harbor-UCLA Medical Center today announced a collaboration to translate research in genetically driven diseases and cancers into potential treatments for patients. “The Lundquist Institute is renowned for its scientific research and drug discoveries, and we look forward to developing a close relationship with their talented scientists in the hope of translating their discoveries into medicines with meaningful benefit for patients,” said BridgeBio CEO and Founder Neil Kumar, Ph.D. Under the established two-year partnership, BridgeBio will work closely with The Lundquist Institute researchers to identify programs that may have the potential to become therapies for patients with genetically driven conditions and cancers. BridgeBio will potentially sponsor research programs and support the development of Lundquist programs and clinical investigations through its licensing and affiliate development model. “By coupling our world-class scientific discoveries with the resources and well-seasoned team at BridgeBio, we have the opportunity to create advancements in therapeutics for genetic diseases,” said Rubayath Mohsen, M.S., Manager of Business Development and Technology Transfer from The Lundquist Institute. “Based on their track record in working closely with researchers, we are optimistic about developing our technologies with BridgeBio and look forward to seeing what we can do together to develop new therapeutics for patients in need.” BridgeBio partners with top academic and research institutions throughout the U.S., including The Lundquist Institute, to support early, promising research in genetically driven diseases and cancers with clear genetic drivers. Today BridgeBio also announced formal partnerships with Brown University, GlycoNet, Oregon Health & Science University, Roswell Park Comprehensive Cancer Center, University of California, Davis and University of California, San Diego – for a total of 20 partnerships between BridgeBio and leading academic and research institutions to date. For a list of some of the institutions BridgeBio is partnered with, please visit Our Partners page. With trust, respect and science at the forefront of all collaborations, BridgeBio will continue developing similar long-term partnerships to support its mission of pioneering critical medicines for patients with certain cancers and genetically driven conditions as quickly and safely as possible. About The Lundquist Institute: "Research with Reach"™The Lundquist Institute is an engine of innovation with a global reach and a 69-year reputation of improving and saving lives. With its new medical research building, its state-of-the-art incubator, “BioLabs at The Lundquist,” existing laboratory and support infrastructure, and a 15-acre tech park in the planning stages, the Lundquist Institute serves as a hub for the Los Angeles area’s burgeoning biotech scene. The research institute has over 100 principal investigators (PhDs, MDs, and MD/PhDs) working on more than 600 research studies, including therapies for numerous, and often fatal orphan diseases. Find out more at https://lundquist.org. About BridgeBio Pharma: BridgeBio is a biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio’s pipeline of over 30 development programs ranges from early science to advanced clinical trials and its commercial organization is focused on delivering the company’s first approved therapy. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com. BridgeBio Pharma Forward-Looking StatementsThis press release contains forward-looking statements. Statements we make in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements, including statements relating to expectations, plans, and prospects regarding our ability to build on The Lundquist Institute’s scientific innovation and genetic disease research and translate them into meaningful medicines for patients in need, the success of current and future relationships with third-party collaborators and academic partners, and the potential ability of our product candidates to treat genetically driven diseases and cancers with clear genetic drivers, reflect our current views about our plans, intentions, expectations, strategies and prospects, and are based on the information currently available to us and on assumptions we have made and are not forecasts, promises nor guarantees. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by these forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, the success of our product candidates to treat genetically driven diseases and cancers with clear genetic drivers, the success of our collaboration with The Lundquist Institute, as well as those risks set forth in the Risk Factors section of BridgeBio Pharma’s most recent Annual Report on Form 10-K and BridgeBio Pharma’s other SEC filings. Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. The Lundquist Institute Contact: Max Benavidez The Lundquist Institutemax.benavidez@lundquist.org (310) 200-2682 BridgeBio Contact: Grace RauhBridgeBio Pharma, Inc.Grace.rauh@bridgebio.com(917) 232-5478
Proxy adviser Glass Lewis has recommended shareholders oppose re-electing Andreas Gottschling to Credit Suisse's board of directors, saying as chair of the board's risk committee he should bear ultimate accountability for recent troubles related to Greensill and Archegos at the bank. "In our view, in order to regain shareholder trust in light of the substantial financial and reputational damage that the company is facing as a result of the aforementioned matters, shareholders would be better served by a change in leadership of the risk committee," Glass Lewis said on Tuesday.
Yahoo Home